Biofrontera Inc Total Assets
Biofrontera Inc total assets. Based on the latest financial reports, Biofrontera Inc (BFRI) holds total assets worth $24.06 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BFRI market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Biofrontera Inc (2019–2025)
Total assets of Biofrontera Inc from 2019 to 2025. This chart illustrates how Biofrontera Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Biofrontera Inc for real-time trading data and today's change.
Biofrontera Inc - Asset Composition Analysis
Biofrontera Inc Total Assets Breakdown (December 2025)
Biofrontera Inc total assets breakdown as of December 2025. Biofrontera Inc's total assets of $24.06 Million consist of 63.3% current assets and 36.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.4% |
| Accounts Receivable | $7.29 Million | 25.5% |
| Inventory | $1.43 Million | 5.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.65 Million | 9.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Biofrontera Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Biofrontera Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biofrontera Inc's current assets represent 63.3% of total assets in 2025, a decrease from 81.6% in 2019.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2025, down from 25.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 14.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 25.5% of total assets.
Biofrontera Inc Competitors by Total Assets
Key competitors of Biofrontera Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Biofrontera Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.18 | 0.96 | 0.90 |
| Quick Ratio | 1.08 | 0.75 | 0.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.89 Million | $-872.00K | $-1.15 Million |
Biofrontera Inc - Advanced Valuation Insights
This section examines the relationship between Biofrontera Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | 29.2% |
| Total Assets | $28.56 Million |
| Market Capitalization | $13.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biofrontera Inc's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biofrontera Inc's assets grew by 29.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biofrontera Inc (2019–2025)
The table below shows the annual total assets of Biofrontera Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $28.56 Million | +29.24% |
| 2024-12-31 | $22.10 Million | -20.88% |
| 2023-12-31 | $27.93 Million | -45.11% |
| 2022-12-31 | $50.88 Million | -4.39% |
| 2021-12-31 | $53.22 Million | +120.48% |
| 2020-12-31 | $24.14 Million | -16.05% |
| 2019-12-31 | $28.75 Million | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more